SAN DIEGO, Sept. 11 /PRNewswire-FirstCall/ -- CryoCor, Inc. (Nasdaq: CRYO), a medical device company focused on the treatment of cardiac arrhythmias, announced today that it has been invited to participate in a Food and Drug Administration (FDA) panel meeting to be held on September 20, 2007 from 8:00 am to 6:00 pm ET in Gaithersburg, Maryland. The FDA panel committee will discuss and make recommendations regarding clinical trial designs for cardiac ablation devices designed to treat patients with medically refractory atrial fibrillation.
Helen Barold, M.D., Chief Medical Officer of CryoCor, said, "We look forward to adding our experience to this general panel discussion on clinical trials for atrial fibrillation ablation."
CryoCor is a medical technology company that has developed and manufactures a disposable catheter system based on its proprietary cryoablation technology for the minimally invasive treatment of cardiac arrhythmias. The Company's product, the CryoCor Cardiac Cryoablation System, or the Cryoablation System, is designed to treat cardiac arrhythmias through the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue. The Cryoablation System has been approved in Europe for the treatment of atrial fibrillation, and atrial flutter, the two most common and difficult to treat arrhythmias, since 2002. In the United States, CryoCor is conducting a pivotal trial to evaluate the safety and efficacy of the Cryoablation System for the treatment of atrial fibrillation and the Cryoablation System has been approved for the treatment of right atrial flutter. For more information please visit the Company's website at http://www.cryocor.com.
Forward Looking Statements
The statements in this press release that are not descriptions of historical facts are forward-looking statements that are subject to risks and uncertainties. The actual events or results may differ materially from those projected in such forward-looking statements due to a number of factors and the risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company expressly disclaims any intent or obligation to update any of these forward-looking statements.
CryoCor, Inc. The Ruth Group
Gregory J. Tibbitts Nick Laudico / Zack Kubow
Chief Financial Officer (investors)
(858) 909-2200 (646) 536-7030 / 7020
Jason Rando (media)
|SOURCE CryoCor, Inc.|
Copyright©2007 PR Newswire.
All rights reserved